PROTEIN POLYMER TECHNOLOGIES NEW PRODUCT SHOWCASE ATTRACTS ATTENTION AT SOCIETY OF INTERVENTIONAL RADIOLOGY 31st ANNUAL MEETING

 

 

SAN DIEGO, APRIL 12 -- Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI), in partnership with Surgica Corporation, is pleased to announce that they successfully introduced three new convenience kits packaged with Surgica’s proprietary foam embolization products during the Society of Interventional Radiology 31st Annual Scientific Meeting which took place in Toronto, Canada.
Capturing the interest of physicians attending the conference was the MaxiStat™ New Product Display. Packaged individually dry in a vial, MaxiStat™ particles offer the advantages of a larger-sized spherical PVA foam embolization particle as an alternative to small coils for up to medium-sized vessels. The particles can be hydrated directly using the physician’s preferred injection fluid.
Based on Surgica’s patent-pending manufacturing process, MaxiStat™ has a traditional PVA foam composition, with a unique new foam structure. The particles are consistently spherical, but larger than any spherical particle that has been developed commercially for embolization. In addition, the particles are both compressible and resilient. After delivery of a 4 mm particle through a 0.38” guidewire compatible catheter, the particle immediately recovers to its original dimensions.
Also introduced at the conference were PVA Plus™ and spherical MicroStat™ foam embolization particles pre-packaged dry in sterile syringes. These new convenience kits contain all of the components required to prepare the particles for delivery.
Embolization, a minimally invasive procedure performed by interventional radiologists, is used to treat a variety of medical conditions including neurovascular conditions, uterine fibroids and inoperable liver cancer. PPTI estimates a conservative annual market potential for embolization could exceed $400 million in the U.S. and $800 million worldwide.

 

 

To schedule media interviews or request product images, please contact Bryan deCastro or Carole Boucard.

 

Contacts

Investor Contact: Erin Davis Director of Communications and Investor Relations Protein Polymer Technologies, Inc. (858) 558-6064 x 120 edavis@ppti.com

Media Contact: Bryan deCastro, (631) 495-9177 Carole Boucard, (954) 370-2524 Creative Public Relations

About Protein Polymer Technologies

Protein Polymer Technologies, Inc. is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies’ proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The Company is headquartered in San Diego, California. For additional information about the Company, please visit www.ppti.com.
To date, PPTI has been issued twenty-six U.S. patents on its core technology with corresponding issued and pending patents in key international markets.

Safe Harbor

This press release contains forward-looking statements that are based on management’s views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company’s activities include raising adequate capital to continue operations, scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company’s 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.